Afamelanotide
CosmeticFDA-approved ฮฑ-MSH analogEstablished
FDA-approved ฮฑ-MSH analog implant (SCENESSE) to increase pain-free light exposure in adults with erythropoietic protoporphyria. 16 mg subcutaneous implant every 2 months.
For research use only.
Key Facts
- CAS
- 75921-69-6
- Molecular Weight (MW)
- 1646.9 g/mol
- Half-life
- ~30 minutes (plasma); ~15 h (from implant)
- Unit
- mcg
- Administration Route
- Subcutaneous implant
- Frequency
- Every 2 months
- Last updated
- 8/23/2026
- Targets
- MC1RMelanocytes
Overview
FDA-approved ฮฑ-MSH analog implant (SCENESSE) to increase pain-free light exposure in adults with erythropoietic protoporphyria. 16 mg subcutaneous implant every 2 months.
Protocol
- Dosage Range
- 16 mg implant
- Frequency
- Every 2 months
- Cycle
- Long-term use as prescribed
- Administration Route
- Subcutaneous implant
- Reconstitution Guide
- Subcutaneous implant - no reconstitution needed
Science
Mechanism of Action
Potent MC1 receptor agonist that increases eumelanin synthesis independently of UV exposure, providing photoprotection in EPP.
Targets
MC1RMelanocytes
Studies
- Afamelanotide for erythropoietic protoporphyriaโ Journal/year not available
Benefits
Increases pain-free light exposure in EPPStimulates eumelanin
Potential Side Effects
- Nausea
- Implant-site reactions
- Headache
- Hyperpigmentation
References
- FDA label โ SCENESSEExternal link ยท Year โ
- NEJM EPP trial (PMID 26004767)External link ยท Year โ